Actionable news
0
All posts from Actionable news
Actionable news in BMY: BRISTOL-MYERS SQUIBB CO.,

NPS+ HIV (US)

NEW YORK, April 19, 2016 /PRNewswire/ -- Satisfaction is running high for HIV treatments in the US Market. But Infectious Disease specialists show a clear preference for fixed-dose combinations. Find out how single-pill monotherapies compare, which 3 brands are fighting for first place, and how your brand measures up.

FirstView's NPS+ HIV report compares brand loyalty for 8 major HIV treatments—information you can use to improve your brand's health, and boost your market share.

Based on your net promoter score (NPS), the report shows you how likely doctors are to recommend your brand—and your competitors. A detailed breakdown of brand associations helps you see which marketing messages are likely to succeed, while a unique "Brand DNA" section reveals doctors' candid thoughts about your brand.

Intuitive, easy-to-use KPIs highlight areas for improvement and make your next steps crystal clear.

Not your market? Click here to see the EU5 Edition.

Get Answers to Key Questions about HIV Treatments

Evotaz (Atazanavir/Cobicistat; Bristol-Myers Squibb/Gilead): Is lack of experience with Evotaz stopping doctors from recommending it?
Intelence (Entravirine; Janssen Pharma): Intelence and Evotaz have similar NPS scores. Which has more promoters?
Isentress (Raltegravir; Merck & Co.): What other drug do some surveyed doctors prefer to Isentress?
Selzentry (Maraviroc; ViiV Healthcare): Is the need for complicated lab tests preventing doctors from recommending Selzentry?
Stribild (Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead): Which brand stands to gain more market share by winning over detractors, Stribild or Triumeq?
Triumeq (Abacavir/dolutegravir/lamivudine; ViiV Healthcare): Promoters highlight Triumeq's ease of use, but is it a big driver of recommendations?
Truvada (Emtricitabine/tenofovir disoproxil fumarate; Gilead): Truvada, Triumeq and Stribild have nearly the same number of Promoters. Which has the higher NPS?
Viread (Tenofovir disoproxil fumarate; Gilead): In Europe, Viread has a low NPS and a lot of Detractors. Is it doing better in the US...


More